A PYMNTS Company

Ireland/US: Actavis nabs $25B acquisition deal

By  |  February 18, 2014

Ireland-based generic drug maker Actavis announced Tuesday it reached a deal to acquire US rival Forest Laboratories, a $25 billion merger that further consolidates the pharmaceutical industry.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Reports say Actavis pursued its competitor in efforts to strengthen its specialty pharmaceuticals portfolio. Both companies have approved of the acquisition soon after Actavis announced a separate, $8.2 billion buyout of rival Warner Chilcott last year.

    Actavis has been at the center of the debate over so-called pay-for-delay deals, in which brand name companies pay generic drug makers to delay the sale of their cheaper versions of drugs.

    Full Content: The Deal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.